Furthermore, CSF TMEM119 could be used as an objective readout on microglia activity/stability in AD therapeutic studies and the monitoring of AD patients already receiving US Food and Drug Administration‐ and European Medicines Agency‐approved therapies, complementing the panel of fluid neuronal and astrocytic markers currently in use. Here, TMEM119 is linked to Alzheimer disease.